07:00 , Jul 20, 2009 |  BC Week In Review  |  Clinical News

MGAWN1: Phase II started

MacroGenics began the double-blind, placebo-controlled, North American Phase II PARADIGM trial to evaluate a single dose of 30 mg/kg intravenous MGAWN1 in about 60 patients with suspected CNS infections due to WNV. In 2006, MacroGenics...
07:00 , Jul 16, 2007 |  BC Week In Review  |  Clinical News

MGAWN1: Phase I start

This quarter, MacroGenics will start a dose-escalation Phase I trial in healthy volunteers. MacroGenics Inc. , Rockville, Md.   Product: MGAWN1   Business: Infectious   Molecular target: Domain lll of West Nile virus E-protein  ...